302 related articles for article (PubMed ID: 21530589)
1. Oral immunization with live Lactococcus lactis expressing rotavirus VP8 subunit induces specific immune response in mice.
Marelli B; Perez AR; Banchio C; de Mendoza D; Magni C
J Virol Methods; 2011 Jul; 175(1):28-37. PubMed ID: 21530589
[TBL] [Abstract][Full Text] [Related]
2. Oral immunization of mice with Lactococcus lactis expressing the rotavirus VP8* protein.
Rodríguez-Díaz J; Montava R; Viana R; Buesa J; Pérez-Martínez G; Monedero V
Biotechnol Lett; 2011 Jun; 33(6):1169-75. PubMed ID: 21302132
[TBL] [Abstract][Full Text] [Related]
3. Rotavirus vp7 antigen produced by Lactococcus lactis induces neutralizing antibodies in mice.
Perez CA; Eichwald C; Burrone O; Mendoza D
J Appl Microbiol; 2005; 99(5):1158-64. PubMed ID: 16238746
[TBL] [Abstract][Full Text] [Related]
4. Yeast expression of the VP8* fragment of the rotavirus spike protein and its use as immunogen in mice.
Andrés I; Rodríguez-Díaz J; Buesa J; Zueco J
Biotechnol Bioeng; 2006 Jan; 93(1):89-98. PubMed ID: 16193515
[TBL] [Abstract][Full Text] [Related]
5. Homotypic protection against rotavirus-induced diarrhea in infant mice breast-fed by dams immunized with the recombinant VP8* subunit of the VP4 capsid protein.
Gil MT; de Souza CO; Asensi M; Buesa J
Viral Immunol; 2000; 13(2):187-200. PubMed ID: 10892999
[TBL] [Abstract][Full Text] [Related]
6. Characterization and protective efficacy in an animal model of a novel truncated rotavirus VP8 subunit parenteral vaccine candidate.
Xue M; Yu L; Che Y; Lin H; Zeng Y; Fang M; Li T; Ge S; Xia N
Vaccine; 2015 May; 33(22):2606-13. PubMed ID: 25882173
[TBL] [Abstract][Full Text] [Related]
7. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.
Parez N; Fourgeux C; Mohamed A; Dubuquoy C; Pillot M; Dehee A; Charpilienne A; Poncet D; Schwartz-Cornil I; Garbarg-Chenon A
J Virol; 2006 Feb; 80(4):1752-61. PubMed ID: 16439532
[TBL] [Abstract][Full Text] [Related]
8. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
[TBL] [Abstract][Full Text] [Related]
9. Mucosal immunization with a ricin toxin B subunit-rotavirus NSP4 fusion protein stimulates a Th1 lymphocyte response.
Choi NW; Estes MK; Langridge WH
J Biotechnol; 2006 Jan; 121(2):272-83. PubMed ID: 16181698
[TBL] [Abstract][Full Text] [Related]
10. Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies.
García-Díaz A; López-Andújar P; Rodríguez Díaz J; Montava R; Torres Barceló C; Ribes JM; Buesa J
Vaccine; 2004 Dec; 23(4):489-98. PubMed ID: 15530697
[TBL] [Abstract][Full Text] [Related]
11. Genetic diversity of G1P[8] rotavirus VP7 and VP8* antigens in Finland over a 20-year period: No evidence for selection pressure by universal mass vaccination with RotaTeq® vaccine.
Hemming M; Vesikari T
Infect Genet Evol; 2013 Oct; 19():51-8. PubMed ID: 23831933
[TBL] [Abstract][Full Text] [Related]
12. Live attenuated human rotavirus vaccine, Rotarix.
Bernstein DI
Semin Pediatr Infect Dis; 2006 Oct; 17(4):188-94. PubMed ID: 17055369
[TBL] [Abstract][Full Text] [Related]
13. Systemic and intestinal antibody responses to NSP4 enterotoxin of Wa human rotavirus in a gnotobiotic pig model of human rotavirus disease.
Iosef C; Chang KO; Azevedo MS; Saif LJ
J Med Virol; 2002 Sep; 68(1):119-28. PubMed ID: 12210439
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease.
El-Attar L; Oliver SL; Mackie A; Charpilienne A; Poncet D; Cohen J; Bridger JC
Vaccine; 2009 May; 27(24):3201-8. PubMed ID: 19446192
[TBL] [Abstract][Full Text] [Related]
15. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
Siadat-Pajouh M; Cai L
Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
[TBL] [Abstract][Full Text] [Related]
16. VP8* antigen produced in tobacco transplastomic plants confers protection against bovine rotavirus infection in a suckling mouse model.
Lentz EM; Mozgovoj MV; Bellido D; Dus Santos MJ; Wigdorovitz A; Bravo-Almonacid FF
J Biotechnol; 2011 Nov; 156(2):100-7. PubMed ID: 21893114
[TBL] [Abstract][Full Text] [Related]
17. Passive protection to bovine rotavirus (BRV) infection induced by a BRV VP8* produced in plants using a TMV-based vector.
Pérez Filgueira DM; Mozgovoj M; Wigdorovitz A; Dus Santos MJ; Parreño V; Trono K; Fernandez FM; Carrillo C; Babiuk LA; Morris TJ; Borca MV
Arch Virol; 2004 Dec; 149(12):2337-48. PubMed ID: 15338319
[TBL] [Abstract][Full Text] [Related]
18. Surface Display of Antigen Protein VP8* of Porcine Rotavirus on
Li W; Feng J; Li J; Li J; Wang Z; Khalique A; Yang M; Ni X; Zeng D; Zhang D; Jing B; Luo Q; Pan K
Molecules; 2019 Oct; 24(20):. PubMed ID: 31652492
[TBL] [Abstract][Full Text] [Related]
19. A Nanoparticle-Based Trivalent Vaccine Targeting the Glycan Binding VP8* Domains of Rotaviruses.
Xia M; Huang P; Jiang X; Tan M
Viruses; 2021 Jan; 13(1):. PubMed ID: 33419150
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults.
Fix AD; Harro C; McNeal M; Dally L; Flores J; Robertson G; Boslego JW; Cryz S
Vaccine; 2015 Jul; 33(31):3766-72. PubMed ID: 26065919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
